IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2012 by Sheba Medical Center.
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Sponsor:
Sheba Medical Center
Information provided by (Responsible Party):
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00287131
First received: February 2, 2006
Last updated: March 28, 2012
Last verified: March 2012
| Tracking Information | ||||
|---|---|---|---|---|
| First Received Date ICMJE | February 2, 2006 | |||
| Last Updated Date | March 28, 2012 | |||
| Start Date ICMJE | January 2006 | |||
| Estimated Primary Completion Date | December 2012 (Final data collection date for primary outcome measure) | |||
| Current Primary Outcome Measures ICMJE |
Response rate and toxicity [ Time Frame: 6 months ] | |||
| Original Primary Outcome Measures ICMJE |
Response rate and toxicity | |||
| Change History | Complete list of historical versions of study NCT00287131 on ClinicalTrials.gov Archive Site | |||
| Current Secondary Outcome Measures ICMJE | Not Provided | |||
| Original Secondary Outcome Measures ICMJE | Not Provided | |||
| Current Other Outcome Measures ICMJE | Not Provided | |||
| Original Other Outcome Measures ICMJE | Not Provided | |||
| Descriptive Information | ||||
| Brief Title ICMJE | Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients | |||
| Official Title ICMJE | Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients | |||
| Brief Summary | Metastatic melanoma is an aggressive and highly malignant cancer. The five-year survival rate of patients with metastatic disease is less than 5% with a median survival of only 6-10 months. Drugs like Dacarbazin (DTIC) as a single agent or in combination with other chemotherapy agents, have a response rate of 15-30%, but the duration of response is usually short, with no impact on survival. Interleukin-2 (IL-2) based immunotherapy has shown more promising results. This form of therapy has a similar response rate with some patients achieving a durable complete response. Recently the National Institute of Health (NIH) reported that by using lympho-depleting chemotherapy, followed by an adoptive transfer of large numbers of anti-tumor specific tumor-infiltrating lymphocytes (TIL), an objective regression was achieved in 51% of patients with metastatic melanoma. Objectives: To introduce the TIL technology to advanced metastatic melanoma patients in Israel. |
|||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase | Phase 2 | |||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
|||
| Condition ICMJE | Metastatic Melanoma | |||
| Intervention ICMJE | Procedure: Procedure - Adoptive cell transfer
Procedure - Adoptive cell transfer |
|||
| Study Arms | Not Provided | |||
| Publications * |
|
|||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Unknown status | |||
| Estimated Enrollment ICMJE | 70 | |||
| Estimated Completion Date | November 2013 | |||
| Estimated Primary Completion Date | December 2012 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
|||
| Sex/Gender |
|
|||
| Ages | 18 Years and older (Adult, Senior) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Israel | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00287131 | |||
| Other Study ID Numbers ICMJE | SHEBA-04-3518-JS-CTIL | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| Plan to Share Data | Not Provided | |||
| IPD Description | Not Provided | |||
| Responsible Party | Sheba Medical Center | |||
| Study Sponsor ICMJE | Sheba Medical Center | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
|
|||
| PRS Account | Sheba Medical Center | |||
| Verification Date | March 2012 | |||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
||||